Olmesartan Medoxomil/Levamlodipine

奥美沙坦酯/左旋氨氯地平

Report date: 2025/03/31 20:00:44

Base Information

Drug NameOlmesartan Medoxomil/Levamlodipine
Drug Alias Name奥美沙坦酯左氨氯地平片
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Olmesartan MedoxomilLevamlodipine Besylate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Front Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Front Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A